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Summary
Akt contributes to tumorigenesis by inhibiting apoptosis. Here we establish that Akt is required for normal cell proliferation
and susceptibility to oncogenesis independently of its antiapoptotic activity. Partial ablation of Akt activity by deleting Akt1
inhibits cell proliferation and oncogenesis. These effects are compounded by deleting both Akt1 and Akt2. In vivo, Akt1 null
mice are resistant to MMTV-v-H-Ras-induced tumors and to skin carcinogenesis. Thus, partial ablation of Akt activity is
sufficient to suppress tumorigenesis in vitro and in vivo. The effect of Akt deficiency on cell proliferation and oncogenesis
is p53 independent but mTORC1 dependent. Surprisingly, upon mTORC1 hyperactivation, the reduction in Akt activity does
not impair cell proliferation and susceptibility to oncogenic transformation; thus, Akt may mediate these processes exclu-
sively via mTORC1.Introduction
Akt, also known as protein kinase B (PKB), is an evolutionarily
conserved serine/threonine kinase. Mammalian cells express
three Akt isoforms (Akt1–3) encoded by three separate genes.
The amino acid sequences of the three isoforms are almost
identical; relative expression of these isoforms, however, differs
in various mammalian tissues. Akt is activated by extracellular
signals that activate PI3K. For instance, upon activation, growth
factor receptors activate p110 (the catalytic subunit of PI3K) ei-
ther by recruiting p85 (the regulatory subunit of PI3K) or by acti-
vating Ras, which can directly activate p110. Upon activation,
p110 phosphorylates phosphoinositides (PI) at the D3 position
of the inositol ring to generate PI (3,4,5) P3 (PIP3). The rate-lim-
iting step in Akt activation is the binding of PIP3 to the pleckstrin
homology (PH) domain of Akt and subsequent translocation of
Akt to the plasma membrane, where it is phosphorylated on
a threonine in the catalytic domain and a serine in the C-terminal
regulatory domain. These modifications are required for full ac-
tivation. The kinase that phosphorylates the threonine is PDK1;
the kinase that phosphorylates the serine was recently identified
as mTORC2, which is a complex containing the mammalianCANCER CELL 10, 269–280, OCTOBER 2006 ª2006 ELSEVIER INC. DOtarget of rapamycin (mTOR) and Rictor (Sarbassov et al.,
2005). Antagonizing PI3K activity can negatively regulate the
activity of Akt. PTEN (for ‘‘phosphatase and tensin homolog
deleted from chromosome 10’’) is a 3-phosphoinositide phos-
phatase that negatively regulates Akt activity by reducing the
intracellular level of PIP3 produced by PI3K (Parsons and Simp-
son, 2003).
Akt could phosphorylate a large number of intracellular tar-
gets (Lawlor and Alessi, 2001), only a few of which are evolution-
arily conserved. mTORC1, a rapamycin-sensitive kinase, com-
prises mTOR and Raptor and is a conserved downstream
effector of Akt, which is considered as a therapeutic target in
cancer (Thomas, 2006). The principal functions of mTORC1
are to mediate ribosome biogenesis and mRNA translation via
activation of S6 kinase and inhibition of the repressor of mRNA
translation, eIF4E binding protein (4E-BP), thereby determining
cell mass (Hay and Sonenberg, 2004). Akt can activate mTORC1
through direct phosphorylation of tuberous sclerosis complex 2
(TSC2), which otherwise inhibits mTORC1 activity (Inoki et al.,
2002; Manning et al., 2002). Akt can also indirectly inhibit
TSC2 via inhibition of AMPK (Hahn-Windgassen et al., 2005).
Tuberous sclerosis complex 1 (TSC1) and TSC2 form aS I G N I F I C A N C E
Akt is frequently activated in human cancers and therefore is an attractive therapeutic target. Whether partial ablation of Akt activity is
sufficient to inhibit tumorigenesis, however, remains unknown. We demonstrate that partial ablation of total Akt activity or selective
inhibition of Akt1 could be an efficient general therapeutic approach for cancer. Our results show that mTORC1 is the most critical
downstream effector of Akt required for cell proliferation and tumorigenesis. Although inhibitors of mTORC1 have been considered
for cancer therapy, they also activate Akt and may not override the antiapoptotic activity of Akt. Because partial ablation of Akt
activity may be sufficient to inhibit both mTORC1 and the antiapoptotic effect of Akt, it could be a successful therapeutic approach.I 10.1016/j.ccr.2006.08.022 269
A R T I C L Eheterodimer, which functions as a GTPase-activating protein
(GAP) that inhibits the activity of Rheb, a small GTPase required
for mTORC1 activation (Hay and Sonenberg, 2004). In Tsc2 or
Tsc1 null cells, mTORC1 is constitutively activated indepen-
dently of growth factors and Akt, consistent with an inhibitory
role for TSC2. In contrast, Akt activity is markedly reduced in
these cells, which is attributed to a negative feedback mecha-
nism (Harrington et al., 2005).
Akt is frequently hyperactivated in human cancers via multiple
mechanisms. Inactivating mutations or deletions of the tumor
suppressor PTEN, which lead to Akt activation, occur frequently
in human cancers with a high incidence in prostate and endome-
trial cancers, glioblastoma, and melanoma (Sansal and Sellers,
2004). In addition, haplodeficiency of PTEN in mice elicits a wide
range of tumors (Di Cristofano et al., 1998; Podsypanina et al.,
1999; Suzuki et al., 1998). Amplification and overexpression of
the gene encoding p110 isoform also occur in a subset of human
cancers (Hennessy et al., 2005). More recently, mutations in one
of the genes encoding p110 (p110a) have been observed in
a large number of human cancers (Samuels et al., 2004); these
mutations likely activate Akt (Kang et al., 2005). Activating muta-
tions of Ras, which can potentially activate Akt, occur in about
one-third of epithelial tumors (Downward, 2003). Also, Akt
gene amplification has been observed in a subset of human can-
cers (Hennessy et al., 2005). Thus, Akt appears to be hyperacti-
vated in the majority of human cancers, which thus implies that
activation of Akt plays a pivotal role in the genesis of cancer
(Hay, 2005; Hennessy et al., 2005). We have recently shown
that partial ablation of Akt activity by the deletion of Akt1 is
sufficient to inhibit the development of tumors in Pten+/2 mice
(Chen et al., 2006). However, it is not known whether partial
ablation of Akt activity is sufficient to inhibit tumors induced by
other mechanisms. Furthermore, the exact mechanisms by
which activation of Akt exerts its effect on the genesis of cancer
are not well understood, and the most critical downstream
effectors of Akt required for the genesis of cancer are largely un-
known. The most established function of Akt in mammalian cells
is inhibition of apoptosis, which may contribute to the genesis of
cancer. However, it is unlikely that this function, by itself, is suf-
ficient to explain the frequent activation of Akt in human cancer.
Here, we provide genetic evidence that Akt is required for
cell proliferation and oncogenic transformation, independently
of its antiapoptotic function. Partial ablation of Akt is sufficient
to inhibit proliferation and oncogenic transformation induced
by dominant negative p53 (DN-p53) in combination with acti-
vated Ras (H-Rasvaline12) or by Myc and activated Ras. These re-
sults could be recapitulated in vivo, as Akt1 knockout (KO) mice
are resistant to tumors induced by activated Ras and are less
susceptible to skin carcinogenesis. The mechanism by which
Akt affects cell cycle progression and susceptibility to onco-
genic transformation is independent of p53. We show that
Akt’s functions in cell proliferation and susceptibility to onco-
genic transformation are executed primarily or exclusively by
mTORC1. In TSC2-deficient cells, mTORC1 is constitutively ac-
tivated, but Akt activity is impaired to an even greater extent
than in Akt1/Akt2 double knockout (DKO) cells. However, the
proliferation rate and susceptibility to oncogenic transformation
of TSC2 null cells are not impaired; in fact, these aspects are en-
hanced compared with control cells. The knockdown of Raptor
in Tsc2 null cells decreases mTORC1 activity and elevates Akt
activity but impairs proliferation and oncogenic transformation.270Likewise, restoring mTORC1 activity in Akt-deficient cells
restores normal proliferation and oncogenic transformation.
Thus, mTORC1 appears to be the most critical downstream
effector of Akt in this respect. Taken together, these results pro-
vide insight into the mechanisms by which Akt contributes to the
genesis of cancer and thus have important implications for
cancer therapy.
Results
Akt-deficient MEFs are impaired in cell proliferation
To assess the role of Akt in normal cell proliferation, we isolated
mouse embryo fibroblasts (MEFs) derived from knockout em-
bryos and their wild-type littermates. We found that Akt1 KO
MEFs divided significantly more slowly than wild-type cells.
This was more pronounced in Akt1/Akt2 DKO MEFs (Figure 1A).
This defect in cell proliferation was not due to increased cell
death in Akt-deficient cells because, when cultured in 10%
FBS, Akt1 KO and Akt1/Akt2 DKO cells did not die significantly
more than wild-type cells (Figure 1A).
To further examine the impaired cell proliferation, we analyzed
the rate of entry into the cell cycle. Wild-type (WT), Akt1 knock-
out (KO), and Akt1/Akt2 double knockout (DKO) MEFs were se-
rum starved for 48 hr in 0.1% FBS-containing medium followed
by stimulation with 10% FBS-containing medium. Cells were
pulse labeled with BrdU for 1 hr for each time point, and the per-
centage of cells with labeled nuclei was quantified (Figure 1B).
Loss of Akt1 alone led to a 44% reduction in BrdU incorporation
compared to wild-type cells, whereas loss of both Akt1 and Akt2
led to a 61% reduction. These data, together with the reduction
in cell division rate, imply that Akt is required for normal G1/S
transition.
We immortalized MEFs by infection with a retrovirus encoding
GSE56, a genetic suppressor element that functions as a domi-
nant negative suppressor of p53 (DN-p53) (Zou et al., 2002). Fol-
lowing infection with a high-titer virus and selection with puro-
mycin, we established polyclonal cell lines. We analyzed these
cell lines for cell cycle progression and BrdU incorporation. All
the immortalized cell lines divided faster than the primary cells.
Despite p53 inactivation, however, the cell division rate (Fig-
ure 1C) and entry into the cell cycle (Figure 1D) were still
impaired in the Akt-deficient cells relative to WT. Furthermore,
BrdU incorporation was also impaired in asynchronous cell pop-
ulations (Figure 1E), indicating that DNA synthesis was impaired
throughout the cell cycle and not just upon entry. Similar results
were obtained with MEFs immortalized with p53 shRNA
(Figure 1F). These results imply that the requirement of Akt for
normal cell cycle progression is independent of p53. It has
been suggested that Akt might mediate its effect via p53 and
that Akt decreases the stability of p53 by phosphorylation of
MDM2 (Mayo and Donner, 2001; Zhou et al., 2001). In our anal-
ysis, however, the half-life of p53 was similar in both WT and
Akt1/Akt2 DKO cells (Figure S1 in the Supplemental Data avail-
able with this article online).
Akt1 is the predominantly expressed Akt isoform in MEFs
(Peng et al., 2003 and Figure 1G), and we estimated that total
Akt activity was reduced by about 50% and 80% in Akt1 KO
and the DKO MEFs, respectively (Figure 1G). Interestingly,
Akt2 KO MEFs were not impaired for proliferation (Figure S2),
suggesting that proliferation is impaired only if total Akt activity
is reduced beyond a certain threshold.CANCER CELL OCTOBER 2006
A R T I C L EFigure 1. Akt deficiency impairs cell proliferation and cell cycle entry in a p53-independent manner
A: Cell proliferation rates of primary MEFs derived from wild-type, Akt1 KO, or Akt1/2 DKO 13.5 day embryos. Cells (5 3 104) were seeded onto a 6 cm dish, in
triplicate, in 10% FBS and allowed to grow. Live and dead cells were counted via trypan blue exclusion using a hemacytometer. Error bars represent6SD. The
experiment shown is representative of three separate experiments with cells derived from different groups of littermates.
B: Entry into the cell cycle of primary MEFs. Cells were cultured in 0.1% FBS for 72 hr followed by release into medium containing 10% FBS. Cells were monitored
for BrdU incorporation as described in the Experimental Procedures. Briefly, cells were labeled with BrdU for 1 hr at each time point after release and fixed with
ethanol, the DNA was denatured, and the cells were probed with antibodies and then counterstained with DAPI. BrdU incorporation was measured by count-
ing at least 300 cells from at least five fields of view in duplicate plates. These data represent three separate experiments with cells derived from different
groups of littermates.
C:Cell proliferation rates of DN-p53-immortalized MEFs. Cells (2.53 104) were seeded in a 6 cm dish, in triplicate, in 10% FBS and counted. These data represent
three separate experiments with different immortalized MEF cell lines. Error bars represent 6SD.
D: Cell cycle entry of DN-p53-immortalized MEFs. Cells were incubated in 0.1% FBS for 72 hr followed by release into medium containing 10% FBS. BrdU incorpo-
ration was monitored as described in the Experimental Procedures. These data represent three separate experiments with different immortalized MEF cell lines.
E: Proliferation rate of asynchronously growing DN-p53-immortalized MEFs was measured by pulse labeling cells for 4 hr with BrdU prior to fixation and staining.
BrdU incorporation was carried out as described in the Experimental Procedures and measured by counting at least 300 cells from at least five fields of view in
triplicate plates. These data represent three separate experiments with different immortalized MEF cell lines. Error bars represent 6SD.
F: Primary MEFs were immortalized by p53 knockdown via shRNA. Cells (2.53 104) were seeded onto a 6 cm dish in 10% FBS and counted. The experiment was
performed three times in triplicate. Error bars represent 6SD.
G: Left panel: RT-PCR analysis showing relative expression of the three Akt isoforms in primary MEFs. Right panel: activity of Akt in WT, Akt1 KO, and Akt1/2 DKO
primary MEFs as measured by immunoblotting with an antibody that recognizes pSer473 of Akt (anti-pSer473) following 72 hr of serum starvation and 30 min of
serum stimulation with 10% FBS.To further understand the mechanism by which Akt affects
cell cycle progression, we studied various cell cycle-regulated
proteins in DN-p53 immortalized MEFs upon cell cycle entry.
Cells were serum starved in 0.1% FBS, released into 10%
FBS, and collected at each time point for immunoblotting. pRb
phosphorylation was impaired in Akt1 KO MEFs upon cell cycle
entry (Figure 2A). This could be demonstrated by a mobility shift
to the hyperphosphorylated forms and by using phospho-
specific antibodies directed against sites phosphorylated by
CDK4 or CDK2 (Figure 2A). The phosphorylation of pRb was fur-
ther impaired in Akt1/Akt2 DKO MEFs (data not shown, and also
Figure 8C). These results suggest that both CDK4 and CDK2
activities are impaired upon cell cycle entry. Analysis of the
expression of proteins that regulate cell cycle progression
revealed that cyclin D1 was reproducibly the most affectedCANCER CELL OCTOBER 2006protein. The reduction in cyclin D1 expression was mostly ob-
served following cell cycle entry. The expression of cyclins D2
and D3, however, was not impaired in Akt1 KO MEFs (Figure 2B,
lanes 3–7 and 10–14). In addition, the level of the cyclin-
dependent kinase (CDK) inhibitor p27 was reproducibly elevated
in nonsynchronized proliferating Akt1 KO MEFs (Figure 2B,
lanes 1 and 8) and Akt1/Akt2 DKO MEFs (data not shown), and
following cell cycle entry the reduction in p27 level was slightly
delayed in Akt1 KO MEFs (Figure 2B, lanes 3–7 and 10–14).
Susceptibility to oncogenic transformation is impaired
in Akt-deficient MEFs
Wild-type and Akt KO MEFs were subjected to a cotransforma-
tion assay following infection with retroviruses expressing
H-Rasvaline12 and Myc or H-Rasvaline12 and DN-p53 (Zou et al.,271
A R T I C L E2002). In this assay, transformation is measured by counting the
foci that appear on a monolayer. Akt1 deficiency by itself was
sufficient to reduce susceptibility to oncogenic transformation
with Ras and DN-p53 by about 5-fold and to oncogenic transfor-
mation by Ras and Myc by about 7-fold (Figures 3A and 3B).
When both Akt1 and Akt2 were deleted, the cells were almost
completely resistant to oncogenic transformation. A hallmark
of neoplastic cellular transformation is the ability to grow in an
anchorage-independent manner in the absence of traditional
matrix attachments. To determine if Akt is required for cells to
obtain this transformed state, we infected primary MEFs with
a retrovirus encoding both DN-p53 and H-Rasvaline12 followed
by plating onto agarose-containing media. The Akt1-deficient
cells formed smaller and fewer colonies than WT cells, whereas
the Akt1/Akt2 DKO cells were hardly able to form colonies
Figure 2. Analysis of pRb phosphorylation and cell cycle regulatory proteins
upon cell cycle entry of DN-p53-immortalized cells
A: pRb phosphorylation following cell cycle entry. DN-p53-immortalized
MEFs were incubated in medium containing 0.1% FBS for 72 hr followed by
release into medium containing 10% FBS. Cell extracts were collected at
the indicated times and were subjected to immunoblotting. Top panel:
anti-total pRb, with slower migrating bands representing phosphorylated
pRb; middle panel: anti-pSer780 of pRb; bottom panel: anti-pSer807/811
of pRb. Lanes 1 and 8 represent asynchronously proliferating cells (P). Lanes
2 and 9 represent serum-starved cells in 0.1% FBS (S). Lanes 3–7 and 10–14
represent time points following release into medium containing 10% FBS.
B: Expression levels of G1 cyclins, CKIs, and CDKs following cell cycle entry.
Cells were treated as in A, and cell lysates were collected for immunoblot-
ting. A representative immunoblot is shown. Lanes 1 and 8 represent asyn-
chronously proliferating cells (P). Lanes 2 and 9 represent serum-starved cells
in 0.1% FBS. Lanes 3–7 and 10–14 represent time points (in hr) following
release into medium containing 10% FBS.272(Figure 3C). Thus, our data show that loss of Akt1 alone or in
combination with Akt2 results in the inability of these cells to
acquire a fully transformed state. Furthermore, when DN-p53-
immortalized MEFs were subjected to Ras transformation,
transformation was still inhibited in Akt-deficient cells (Fig-
ure 3D), although to a lesser extent than observed in the primary
cells. It is unlikely that the antiapoptotic activity of Akt signifi-
cantly contributes to susceptibility to oncogenic transformation
in the conditions of high serum level that were used. Neverthe-
less to directly examine the requirement of Akt for susceptibility
to oncogenic transformation independently of its antiapoptotic
function, we overexpressed Bcl-2 in the cells. Although Bcl-2
overexpression increased the ability of both WT and Akt-
deficient cells to grow on soft agarose, the Akt-deficient cells
were still impaired, to the same extent, in their ability to be trans-
formed (Figure 3D). In addition, when DN-p53- or p53-shRNA-
immortalized WT MEFs were passaged more than ten times,
they formed foci on a confluent monolayer, whereas Akt1/Akt2
DKO cells did not (Figure 3E). Taken together, these results
imply first that Akt is required for oncogenic transformation in
a p53-independent manner and second that even partial inhibi-
tion of total Akt activity is sufficient to substantially reduce
susceptibility to oncogenic transformation in vitro. Third, Akt is
required for oncogenic transformation regardless of its anti-
apoptotic activity.
Deletion of Akt1 is sufficient to impair tumorigenesis
in vivo
To recapitulate the ability of Akt1 deficiency to suppress onco-
genic transformation in vivo, we first crossed Akt1 KO mice
with MMTV-v-H-Ras mice, in which activated viral Harvey Ras
induces mammary and salivary gland tumors (Sinn et al.,
1987). Akt1+/2/MMTV-v-H-Ras mice were intercrossed to gen-
erate Akt1+/+/MMTV-v-H-Ras and Akt12/2/MMTV-v-H-Ras
mice. The mice were monitored for tumor appearance, and
the percentage of tumor-free mice was calculated (Figure 4A).
Deletion of Akt1 was sufficient to markedly delay the onset of tu-
mor appearance from 11 weeks in Akt1+/+/MMTV-v-H-Ras mice
to 29 weeks in Akt12/2/MMTV-v-H-Ras mice. Overall, Akt12/2/
MMTV-vH-Ras mice were dramatically more resistant to tumors
induced by activated Ras when compared with Akt1+/+/MMTV-
v-H-Rasmice. After 50 weeks, we observed that only about 13%
of Akt1+/+/MMTV-v-H-Ras mice remained tumor free, whereas
about 73% of Akt12/2/MMTV-v-H-Ras mice were tumor free.
Thus, these results recapitulated the results we obtained ex
vivo with cells derived from Akt1 KO mice.
We also subjected 129sv/C57BL/6 (1:1) Akt1 KO and WT lit-
termates to skin carcinogenesis (see Experimental Procedures).
As shown in Figure 4B, the number of tumors in Akt1 KO mice
was reduced 2-fold. Tumor size was reduced even further in
Akt1 KO mice compared with their wild-type littermates, and
no tumors larger than 7 mm were observed in Akt1 KO mice
16 weeks after the induction of carcinogenesis (Figure 4B).
Thus, we concluded that the deletion of Akt1 is sufficient to in-
hibit tumorigenesis in vivo, and that partial ablation of Akt activ-
ity is not only sufficient to inhibit oncogenic transformation of
MEFs but also epithelial tumors in vivo. These results have
strong implications for cancer therapy, suggesting that even
partial ablation of Akt activity could be an efficient therapeutic
strategy.CANCER CELL OCTOBER 2006
A R T I C L EFigure 3. Akt-deficient cells are resistant to oncogenic transformation
A: Primary MEFs were subjected to the cotransformation assay. Subconfluent MEFs were infected with empty retrovirus, retrovirus expressing both DN-p53 and
H-Rasvaline12, or retrovirus expressing both Myc and H-Rasvaline12. Cells were allowed to grow past confluency and were fixed and stained to observe foci
formation. These data represent three separate experiments with cells derived from different groups of littermates.
B: Quantitation of foci observed in A. The total number of foci per plate was scored by counting. The experiment was performed in triplicate. These data rep-
resent three separate experiments with cells derived from different groups of littermates. Error bars represent 6SD.
C: Primary MEFs infected with retrovirus expressing both DN-p53 and H-Rasvaline12 were plated in 0.35% agarose-containing medium, as described in the Ex-
perimental Procedures, and allowed to grow with weekly media changes for approximately 6 weeks. The left panel shows representative fields of soft agarose
colonies. The bar graph represents the quantitation of soft agarose colonies. The experiment was performed in triplicate at least three times with cells derived
from different groups of littermates. Error bars represent 6SD.
D:DN-p53-immortalized MEFs were infected with retrovirus expressing H-Rasvaline12 or with both retrovirus expressing H-Rasvaline12 and retrovirus expressing Bcl-2,
as described in the Experimental Procedures. Following selection, polyclonal cell lines were analyzed by soft agarose assays. The bar graph represents the
average number of colonies counted from triplicate plates. Experiments were performed with at least three independent cell lines. Error bars represent6SD.
E: Spontaneous foci formation on a confluent monolayer of late-passage DN-p53-immortalized MEFs. MEFs were passaged at least 15 times and allowed to
grow past confluency for 7–10 days. Cells were fixed and stained as described in the Experimental Procedures to visualize foci.Tsc2 null cells are not impaired in their proliferation rate
and susceptibility to oncogenic transformation despite
diminished Akt activity
To delineate the mechanism by which Akt affects cell prolifera-
tion and oncogenic transformation, we assessed the role of
mTORC1 as a potential downstream effector. Inhibition of
mTORC1 with rapamycin was shown to inhibit cell cycle pro-
gression (Fingar et al., 2004). Akt is required for growth fac-
tor-mediated activation of mTORC1, and mTORC1 activity is
impaired in Akt-deficient cells (Gingras et al., 1998; Hahn-Wind-
gassen et al., 2005; Peng et al., 2003). Akt activates mTORC1 by
inhibiting its upstream negative regulator, TSC2, in the heterodi-
meric complex TSC1/TSC2 (Inoki et al., 2002; Manning et al.,
2002). Thus, in Tsc2 null cells mTORC1 is constitutively active
and does not require growth factors and Akt for its activation
(Zhang et al., 2003). However, as a result of a feedback inhibitory
loop, Akt activity is diminished in Tsc2 null MEFs (Harrington
et al., 2005; Zhang et al., 2003). We found that Akt activity inCANCER CELL OCTOBER 2006p53-deficient Tsc2 null MEFs was reduced to an even greater
extent than in p53-deficient Akt1/Akt2 DKO MEFs (Figure 5A).
Nevertheless, Tsc2 null MEFs proliferated at the same rate as
control heterozygous Tsc2 MEFs (Figures 5B and 5C). In addi-
tion, following cell cycle entry, pRb phosphorylation was not im-
paired in Tsc2 KO MEFs despite the marked reduction in Akt ac-
tivity (data not shown). Moreover, reintroduction of Tsc2 into
Tsc2 null cells, by retrovirus infection followed by the generation
of polyclonal cell line, elevated Akt activity (Figure 6A) with a con-
comitant decrease in mTORC1 activity as measured by 4E-BP1
phosphorylation in the absence of serum (Figure 6B) but mark-
edly decreased proliferation rate (Figures 6C and 6D). The pro-
liferation rate was only modestly reduced when an Akt-phos-
phomimetic mutant of Tsc2 was introduced into the Tsc2 KO
MEFs instead of WT Tsc2 (Figure S3C). Furthermore, the reintro-
duction of Tsc2 dramatically reduced susceptibility to onco-
genic transformation by activated Ras (Figure 6E). We also iso-
lated individual clonal cell lines having increasing levels of TSC2273
A R T I C L Eand examined their ability to overcome contact inhibition. As
shown in Figure 6F, Tsc2 null MEFs formed foci on a confluent
monolayer, which was diminished with increasing TSC2 expres-
sion despite increasing Akt activity. Finally, expression of acti-
vated Akt fully restored susceptibility to oncogenic transforma-
tion by activated Ras of Tsc22/2 cells expressing WT Tsc2 but
not of Tsc22/2 cells expressing a Tsc2 mutant that cannot be
phosphorylated by Akt (Figure S4). Together these results dem-
onstrate that, when mTORC1 is constitutively active, Akt activity
is no longer required to promote cell proliferation and suscepti-
bility to oncogenic transformation. Because inhibition of TSC2
by Akt leads to the activation of mTORC1 and because
mTORC1 activity is impaired in Akt-deficient cells, our results
strongly suggest that mTORC1 is the most critical and possibly
the exclusive downstream effector of Akt required for cell prolif-
eration and susceptibility to oncogenic transformation.
Inhibition of mTORC1 in Tsc2 null cells via knockdown of
Raptor elevates Akt activity but impairs cell proliferation
and susceptibility to oncogenic transformation
To further substantiate the notion that mTORC1 mediates Akt’s
requirement for cell proliferation and susceptibility to oncogenic
Figure 4. Akt1 null mice are resistant to tumorigenesis
A: Akt1+/+/MMTV-v-H-Ras (n = 15) and Akt12/2/MMTV-v-H-Ras (n = 11) mice
were generated as described in the Experimental Procedures. Mice were
monitored weekly and scored for tumors; the percentage of tumor-free
mice is presented.
B: Wild-type and Akt1 KO littermates were subjected to a two-step skin car-
cinogenesis protocol as described in the Experimental Procedures. Tumor
number and size were monitored weekly. Nine mice per group were
treated; animals treated with vehicle alone did not form tumors.274transformation, we first knocked down Raptor in Tsc2 null cells.
Compared with control Tsc2 null cells, Raptor knockdown di-
minished mTORC1 activity but markedly elevated Akt activity
(Figure 7A) due to recovery from the inhibitory feedback loop.
Despite this elevated Akt activity, cell proliferation (Figure 7B)
and susceptibility to Ras-mediated transformation (Figure 7C)
were impaired. In a complementary experiment, we used rapa-
mycin to inhibit mTORC1 activity in WT MEFs and found that it
elevated Akt activity (Figure 7D) but reduced proliferation to
the level observed in Akt1/Akt2 DKO MEFs (Figure 7E). In addi-
tion, rapamycin treatment inhibited the ability of WT MEFs to be
transformed by Ras (Figure S3A). Thus, these results provide
further compelling evidence that mTORC1 is the predominant
downstream effector of Akt-mediated proliferation and onco-
genic transformation.
Overexpression of activated Rheb restores normal
cell proliferation and oncogenic transformation
of Akt1/Akt2 DKO MEFs
The above results, together with our previous observation that
mTORC1 activity is impaired in Akt1/Akt2 DKO MEFs (Hahn-
Windgassen et al., 2005; Peng et al., 2003), suggest that the res-
toration of mTORC1 activity in Akt1/Akt2 DKO MEFs should also
restore proliferation and susceptibility to oncogenic transfor-
mation. Because Rheb acts downstream of TSC2 to activate
mTORC1, we have generated a polyclonal Akt1/Akt2 DKO
MEF line ectopically expressing an activated form of Rheb (Li
et al., 2004) to restore mTORC1 activity in these cells (Figure 8A).
Although this form of Rheb did not constitutively activate
mTORC1 as in TSC2-deficient cells (data not shown), its
Figure 5. Akt activity is impaired in TSC2 KO cells without impairing cell
proliferation
A: Akt activity of DN-p53-immortalized WT and Akt1/2 DKO MEFs, and p53-
deficient TSC2 heterozygous and KO MEFs. Immunoblotting of lysates de-
rived from cells prior to and after serum stimulation with anti-pSer473 Akt.
Lanes 1, 4, 7, and 10 represent serum-deprived cells; lanes 2, 3, 5, 6, 8, 9,
11, and 12 represent serum stimulation with 10% FBS for 5 min or 50 min.
B: Cell proliferation rate of Tsc2 heterozygous and Tsc2 KO MEFs. Cells (1 3
104) were seeded onto a 6 cm dish in 10% FBS and counted.
C: Proliferation rate of asynchronously growing Tsc2 heterozygous cells and
Tsc2 KO MEFs, as measured by pulse labeling cells for 4 hr with BrdU prior to
staining as described in the Experimental Procedures. BrdU incorporation
was measured by counting at least 300 cells from at least five fields of
view. The average of triplicate plates is presented. Error bars represent6SD.CANCER CELL OCTOBER 2006
A R T I C L EFigure 6. Reexpression of TSC2 in Tsc2 KO MEFs
reduces mTORC1 activity with concomitant
decrease in cell proliferation and oncogenic
transformation capacity, despite elevated Akt
activity
A:Akt activity in Tsc2 KO MEFs or Tsc2 KO MEFs ex-
pressing exogenous Tsc2. Immunoblot showing
Akt activity as measured by the phosphorylation
of Ser473 of Akt in Tsc2+/2 MEFs, control Tsc22/2
MEFs, or Tsc22/2 MEFs expressing exogenous
Tsc2 [Tsc22/2 (R)] after serum deprivation (2) fol-
lowed by serum stimulation with 10% FBS for 30
min. The generation of the polyclonal Tsc2 KO
cell line expressing exogenous Tsc2 or vector
control is described in the Experimental Proce-
dures.
B: mTORC1 activity in Tsc2 KO cells and Tsc2 KO
cells expressing exogenous Tsc2. Immunoblot
showing mTORC1 activity, as measured by S6K1
phosphorylation and 4EBP1 phosphorylation via
mobility shift, in Tsc2+/2 MEFs, control Tsc22/2
MEFs, or Tsc22/2 MEFs expressing exogenous
Tsc2 [Tsc22/2(R)] in the presence or absence of
serum.
C: Cell proliferation rates of Tsc2 KO MEFs or Tsc2
KO MEFs expressing exogenous Tsc2. Cells (2.5 3
104) were seeded onto a 6 cm dish in 10% FBS
and counted. The experiment was conducted
at least three times in triplicate. Error bars
represent 6SD.
D: BrdU incorporation rate of Tsc2 KO MEFs and reconstituted Tsc2 KO MEFs. Asynchronously growing cells were pulse labeled for 4 hr with BrdU prior to fixation
and staining. BrdU incorporation was measured by counting at least 300 cells from at least five fields of view in triplicate plates. Error bars represent 6SD.
E: Soft agarose assays for Tsc2 KO MEFs and reconstituted Tsc2 KO MEFs after transformation by H-Rasvaline12. Cells were infected with retrovirus expressing
H-Rasvaline12 and were subjected to soft agarose assay as described in Figure 3D. The experiment was performed at least three times in triplicate. Error bars
represent 6SD.
F: Tsc2 level, Akt activity, and contact inhibition in clonal cell lines expressing exogenous Tsc2. Individual clonal cell lines expressing varying levels of Tsc2 were
isolated as described in the Experimental Procedures. Upper panels: immunoblots showing relative expression of exogenous Tsc2 and Akt activity as measured
using an antibody against pSer473 of Akt, with anti-B-actin serving as a control. Lane 1, TSC22/2; lane 2, clone #1 has a low level of TSC2 expression; lane 3,
clone #2 has a moderate level of TSC2 expression; and lane 4, clone #3 has a high level of TSC2 expression. Bottom panel: contact inhibition and spontaneous
foci formation of the clonal cell lines following 7–10 days of growth past confluency.expression restored the proliferation of Akt1/Akt2 DKO MEFs to
the level observed in WT cells and increased the proliferation
rate of WT cells (Figure 8B). The restoration of cell proliferation
by Rheb is inhibited by rapamycin (Figure S3D). Rheb also re-
stored pRb phosphorylation upon the entry of Akt1/Akt2 DKO
MEFs into the cell cycle (Figure 8C). Finally, Rheb restored the
ability of Akt1/Akt2 DKO MEFs to be transformed by activated
Ras (Figure 8D). Ectopic expression of Rheb in WT MEFs in-
creased their ability to grow on soft agarose, as both the size
and the number of colonies were increased, whereas Rheb ex-
pression in Akt1/2 DKO MEFs increased their ability to grow
on soft agarose to the same level observed for WT MEFs
(Figures 8D and 8E). Thus, we conclude that Akt promotes
cell proliferation and oncogenic transformation predominantly
through the activation of mTORC1.
Discussion
Lesions leading to the hyperactivation of Akt are probably the
most frequent lesions occurring in human cancers (Hay, 2005;
Hennessy et al., 2005). However, it is not completely understood
why hyperactivation of Akt is required and how it contributes to
the genesis of cancer. It is well established that activation of Akt
inhibits apoptosis. However, the antiapoptotic activity of Akt, by
itself, is unlikely sufficient to explain its frequent activation in
human cancers, particularly since hyperactivated Akt alone is
sufficient to transform cells in culture (Aoki et al., 1998) and toCANCER CELL OCTOBER 2006induce tumorigenesis in vivo in transgenic mice (Majumder
et al., 2003). Although activation of Akt has been implicated in
increased cell proliferation, it is not known whether Akt is in
fact required for cell proliferation and susceptibility to oncogenic
transformation. How Akt affects these processes and the iden-
tity of critical downstream effectors also remain largely un-
known. As such, we undertook genetic approaches to address
these issues.
We first demonstrated that partial ablation of Akt activity by
the knockout of Akt1 or both Akt1 and Akt2 genes in MEFs is suf-
ficient to markedly impede cell cycle progression and to inhibit
oncogenic transformation. Akt1 KO MEFs were significantly
more resistant than WT MEFs to transformation induced by ac-
tivated Ras together with Myc or with DN-p53. Akt1/2 DKO
MEFs were much more resistant to oncogenic transformation
than Akt1 KO MEFs, and this correlates directly with the relative
decrease in total Akt activity. Interestingly, the proliferation rate
of Akt2 KO MEFs was not impaired compared with WT MEFs.
Akt2 deletion by itself reduced total Akt activity to a lesser extent
than Akt1 deletion, suggesting that, although partial ablation of
total Akt activity was sufficient to impair cell proliferation and on-
cogenic transformation, this reduced Akt activity needs to be
above a certain threshold. Alternatively, it is possible that Akt1
and Akt2 are functionally distinct with respect to cell proliferation
and oncogenic transformation. However, we do not have any
experimental evidence to support this alternative, and our re-
sults suggest that the effect of Akt1 and Akt2 on cell proliferation275
A R T I C L EFigure 7. Reducing mTORC1 activity by Raptor knockdown, or rapamycin treatment, decreases cell proliferation and oncogenic transformation despite
elevated Akt activity
A: The knockdown of Raptor in Tsc2-KO MEFs following infection with lentivirus expressing Raptor shRNA is described in the Experimental Procedures. Cell lysates
derived from Tsc2-KO MEFs expressing Raptor shRNA or control Tsc2-KO MEFs expressing LacZ shRNA were subjected to immunoblotting using anti-Raptor, anti-
pSer473 Akt, anti-total Akt, and anti-pS6K1.
B: Proliferation rate of LacZ shRNA- or Raptor shRNA-expressing Tsc2 KO MEFs. Cells (2.53 104) were seeded in a 6 cm dish in 10% FBS and counted. The exper-
iment was conducted at least three times in triplicate. Error bars represent 6SD.
C: Soft agarose assays for Tsc2 KO MEFs expressing LacZ shRNA or Raptor shRNA following transformation by H-Rasvaline12. Cells were infected with retrovirus
expressing H-Rasvaline12 and were subjected to the soft agarose assay as described in Figure 3D. The experiment was performed at least three times in tripli-
cate. Error bars represent 6SD.
D: Akt activity following rapamycin treatment. DN-p53-immortalized WT MEFs were treated with vehicle or 20 nM rapamycin for 72 hr and then analyzed by
immunoblotting using anti-pSer473 Akt or anti-total Akt.
E: Growth rate following rapamycin treatment. Wild-type or Akt1/2 DKO immortalized MEFs (2.53 104) were seeded onto a 6 cm dish in the absence or pres-
ence of 20 nM rapamycin and counted. The experiment was performed at least three times in triplicate. Error bars represent 6SD.and oncogenic transformation is additive. Nevertheless, be-
cause our results are limited to MEFs in vitro, we cannot exclude
the possibility that Akt1 and Akt2 are functionally distinct in other
cell types or during tumorigenesis in vivo.
Because Akt phosphorylates MDM2 and enhances its ability
to degrade p53 (Mayo and Donner, 2001; Zhou et al., 2001),
we analyzed the steady-state level and half-life of p53 in WT ver-
sus Akt1/2 DKO MEFs and found no significant difference. Thus,
the remaining Akt3 activity may be sufficient to phosphorylate
MDM2. Indeed, we found that the requirements of Akt activity
for cell proliferation and for transformation with activated Ras
are independent of p53 because Akt1 KO or Akt1/Akt2 DKO
MEFs immortalized by expressing DN-p53 or p53 shRNA were
still impaired in their ability to proliferate and to be transformed
with activated Ras. Interestingly, these effects of Akt on cell pro-
liferation and susceptibility to oncogenic transformation appear
to be independent of its antiapoptotic activity. First, we found no
significant spontaneous increase in apoptosis in Akt-deficient
MEFs when they were cultured in the presence of 10% FBS.
Second, Akt-deficient MEFs were still resistant to oncogenic
transformation even when Bcl-2 was ectopically expressed.
We therefore conclude that, in addition to its antiapoptotic activ-
ity, Akt is required for cell proliferation and oncogenic transfor-
mation regardless of p53 status.276To verify whether Akt deficiency is also sufficient to confer re-
sistance to tumorigenesis in vivo, we first determined whether
Akt1 KO mice were resistant to tumors induced by activated
Ras. We therefore crossed Akt1 KO mice with transgenic
MMTV-v-H-Ras mice, which develop salivary and mammary
gland tumors. Akt1 deletion was sufficient to substantially delay
the onset of tumors and to profoundly increase the resistance to
tumors induced by activated Ras. Additionally, Akt1 KO mice
were markedly more resistant to skin carcinogenesis than
wild-type mice. Thus, the conclusions based on the ex vivo re-
sults with MEFs could be extended to epithelial tumors in vivo
in mice.
It was recently shown that Akt1 deficiency is sufficient to sig-
nificantly attenuate tumor development induced by PTEN defi-
ciency (Chen et al., 2006). However, the results presented
here suggest that partial Akt ablation could be used as a general
approach to inhibit tumorigenesis induced by lesions, which do
not directly activate Akt. Furthermore, because Akt1 KO mice
are not impaired in their life span and may possibly live longer
than wild-type mice (Chen et al., 2006), these results suggest
that partial ablation of Akt could be used as a therapeutic
approach for cancer without eliciting severe physiological con-
sequences. Notably, it was recently suggested that Akt1 sup-
presses metastasis (Wyszomierski and Yu, 2005). However,CANCER CELL OCTOBER 2006
A R T I C L EFigure 8. Proliferation and transformation de-
fects in Akt-deficient cells are rescued by overex-
pressing Rheb
A: mTOR activity in Akt1/2 DKO MEFs express-
ing RhebQ64L. Cell lysates of asynchronously
growing DN-p53-immortalized WT MEFs express-
ing empty vector, Akt1/2 DKO MEFs expressing
empty vector, or Akt1/2 DKO MEFs expressing
Myc-tagged RhebQ64L were subjected to im-
munoblotting with anti-Myc and with anti-
4EBP1 to determine the mobility shift.
B: Proliferation rate of DN-p53-immortalized WT
and Akt1/2 DKO MEFs expressing empty vector
or Myc-tagged RhebQ64L. Cells (2.5 3 104)
were seeded onto a 6 cm dish in triplicate in
10% FBS and counted. The experiment was con-
ducted at least three times on three indepen-
dently derived cell lines. Error bars represent6SD.
C: Phosphorylation of pRb upon cell cycle entry.
Immunoblotting of cell lysates derived from WT
and Akt1/2 DKO immortalized MEFs expressing
empty vector or Myc-tagged RhebQ64L using
antibodies against pSer780 of pRb, total pRb,
and b-actin. Lanes 1, 4, 7, and 10 represent cells
depleted of serum for 72 hr. Lanes 2, 3, 5, 6, 8, 9,
11, and 12 represent time points (in hr) following
release into 10% FBS.
D: Soft agarose assays following H-Rasvaline12
expression in wild-type and Akt1/2 DKO immor-
talized MEFs expressing empty vector or Myc-
tagged RhebQ64L. Cells were infected with
retrovirus expressing H-Rasvaline12 and subjected
to soft agarose assay as described in Figure 3D.
Shown are representative fields from each cell
line at the time of quantitation.
E: Quantitation of colonies counted in triplicate.
The experiment was performed three times
on independently derived cell lines. Error bars
represent 6SD.our preliminary results suggest that the deficiency of Akt1 in-
hibits not only tumor development but also metastasis because,
thus far, every MMTV-v-H-Ras mouse that was examined devel-
oped lung metastasis, whereas in Akt12/2MMTV-v-H-Ras mice,
which developed tumors, we did not observe metastasis.
To elucidate the mechanism by which Akt affects cell cycle
progression, we analyzed proteins that regulate entry into and
progression of the cell cycle. We found that pRb phosphoryla-
tion by both CDK2 and CDK4 is significantly impaired in Akt-de-
ficient cells. However, among the cell cycle regulators that were
tested only the induction of cyclin D1 was impaired upon cell cy-
cle entry, and the p27 level was slightly elevated in proliferating
Akt-deficient cells. Because the reduction in cyclin D1 level was
only observed upon cell cycle entry, it cannot explain the re-
duced proliferation and the resistance to oncogenic transforma-
tion of Akt-deficient cells. Furthermore, cyclin D1 KO MEFs are
not impaired in their ability to be transformed by activated Ras
(Yu et al., 2001). Interestingly, two evolutionarily conserved
downstream effectors of Akt, FOXO and mTORC1, have been
shown to affect the expression of both p27 and cyclin D1 by dif-
ferent mechanisms. Activation of FOXO transcription factors,
which is inhibited by Akt, or the inhibition of mTORC1, which
is activated by Akt, elevate p27 expression and decrease cyclin
D1 expression (Gera et al., 2004; Luo et al., 1996; Schmidt et al.,
2002; Stahl et al., 2002).
The interrelationships between Akt and mTOR (Hay, 2005),
and the observations that the inhibition of mTORC1 attenuatesCANCER CELL OCTOBER 2006cell cycle progression and inhibits pRb phosphorylation (Luo
et al., 1996) and that mTORC1 activity is impaired in Akt-defi-
cient cells (Hahn-Windgassen et al., 2005; Peng et al., 2003),
led us to examine mTORC1 as a potential downstream effector
of Akt required for cell proliferation and oncogenic transforma-
tion. We provided strong evidence, through a series of experi-
ments, that Akt could mediate cell proliferation and oncogenic
transformation exclusively through mTORC1. We took advan-
tage of the feedback inhibition of Akt activity in Tsc2 KO MEFs
to show that, when mTORC1 was hyperactivated, Akt activity
was no longer required for cell proliferation or oncogenic trans-
formation, in contrast to its requirement when mTORC1 is not
hyperactivated. Thus, despite a marked reduction in Akt activity
and FOXO activation (Manning et al., 2005), Tsc2-deficient cells
and Tsc2-proficient cells are equivalent with regard to prolifera-
tion and susceptibility to oncogenic transformation. In contrast,
Akt could not promote cell proliferation and oncogenic transfor-
mation when mTORC1 was inhibited, as ectopic expression of
TSC2 or knockdown of Raptor in Tsc2-deficient cells inhibited
mTORC1, with concomitant reduction in cell proliferation and
oncogenic transformation, despite elevated Akt activity. Finally,
ectopic expression of activated Rheb rescued the phenotype of
Akt-deficient cells by restoring mTORC1 activity in these cells.
Our results showing that mTORC1 activation was sufficient to
recapitulate the functions of Akt in regards to cell proliferation
and oncogenic transformation are consistent with genetic anal-
ysis in Drosophila showing that Tsc1 and Tsc2 are epistatic to277
A R T I C L EPten and that cells doubly deficient for Pten and Tor are indistin-
guishable from cells lacking Tor alone (Zhang et al., 2000). The
results are also consistent with the observation that most
changes in gene expression upon induction of glioblastoma in
mice by activated Ras or Akt occur at the level of mRNA trans-
lation (Rajasekhar et al., 2003). Nevertheless, the exact mecha-
nism(s) by which mTORC1 affects cell proliferation and
oncogenic transformation and the mechanism by which it com-
pensates for Akt activity are not clear. The reported effects of
mTORC1 on p27 and cyclin D1 (Gera et al., 2004; Luo et al.,
1996) could, at least in part, provide a mechanistic explanation.
It is likely, however, that mTORC1 may have a much more global
effect by accelerating general protein synthesis, as protein syn-
thesis determines cell mass, which in turn could determine entry
into the cell cycle and consequent proliferation. Additionally, al-
though speculative, it is possible that hyperactivation of S6K1 by
mTORC1 could compensate at least to some extent for the loss
of Akt activity. Given that proteins targeted by the S6K1 and Akt
kinases have similar consensus phosphorylation motifs, hyper-
activation of S6K1 could lead to the phosphorylation of certain
proteins that are normally phosphorylated by Akt. For instance,
both Akt and S6K1 phosphorylate serine 136 of Bad (Harada
et al., 2001).
Interestingly, as we have previously shown, Akt can activate
mTORC1, at least in part, by maintaining cellular energy metab-
olism (Hahn-Windgassen et al., 2005). Since the ability of Akt to
inhibit apoptosis is coupled to its effect on cellular energy
metabolism (Robey and Hay, 2005), it is possible that the major
impact of Akt on tumorigenesis is via its effect on energy
metabolism.
Finally, our results could have important implications for can-
cer therapy. First, the results suggest that even partial ablation
of Akt activity may be sufficient to inhibit cancer development.
Second, the results could imply that the use of rapamycin deriv-
atives for cancer therapy should be sufficient to inhibit excess
proliferation and tumorigenesis induced by the activation of
Akt as well as by other oncogenes, even in the absence of func-
tional p53. However, rapamycin treatment, unlike the inhibition
of Akt, alone might not be sufficient to overcome the antiapop-
totic activity of Akt, as rapamycin elevates rather than inhibits
Akt activity.
Experimental procedures
Cells and viruses
Akt1 KO, Akt2 KO, and Akt1+/2Akt2+/2 mice (Chen et al., 2001; Peng et al.,
2003) were backcrossed to a C57BL/6 background for six generations.
WT, Akt1 KO, Akt2 KO, and Akt1/2 DKO primary MEFs were harvested
from E13.5 embryos as previously described (Chen et al., 2001; Peng
et al., 2003). Experiments with primary cells were performed no later than
passage 5. To immortalize MEFs, primary cells were infected with a retrovirus
(pBabePuro-GSE56) expressing dominant-negative p53 (Zou et al., 2002).
Following infection and selection with 2 mg/ml puromycin, stable polyclonal
cell lines were generated. Immortalization by p53 knockdown was done fol-
lowing infection with a lentivirus, Plenti6/blockitdest (Invitrogen), expressing
p53 shRNA. Following infection, selection with 7 mg/ml of blasticidin was
done to generate polyclonal cell lines. Tsc2+/2 and Tsc22/2 MEFs were pre-
viously described (Hahn-Windgassen et al., 2005). Cells were routinely cul-
tured in DMEM containing 10% FBS.
Retroviruses were generated following transient transfection of retroviral
vector into Phoenix ecotropic packaging cell line. Retrovirus infection was
carried out for 6–12 hr in the presence of 8 mg/ml polybrene. Antibiotic selec-
tion was carried out 48 hr later until complete loss of uninfected cells, to278generate polyclonal cell lines. To generate clonal cell lines expressing
different levels of Tsc2, individual clones were isolated and propagated. Len-
tiviruses were generated using ViraPower Lentiviral Expression System
(Invitrogen). The individual retroviral and lentiviral vectors used are described
in the Supplemental Data.
Cell proliferation rate
Primary (5 3 104) or immortalized (2.5 3 104) MEFs were plated on 6 cm
dishes and were counted daily. Cells were trypsinized for counting using a
hemacytometer. Primary MEFs were stained with a 0.4% trypan blue solution
and counted with a hemacytometer; positive and negative cells were scored
to distinguish between dead and live cells, respectively. Experiments were
conducted on cells isolated from independent sets of littermates. At least
three experiments, in triplicate, were performed for each cell line.
BrdU incorporation
Cells (2.53 105) were plated in each well of a 6-well dish. Cells were starved
in 0.1% FBS in DMEM for 48–72 hr and then were stimulated to reenter the
cell cycle by addition of 10% FBS in DMEM. At each time point, cells were
pulse labeled with 3 mg/ml BrdU for 1 hr and then fixed with 70% ethanol.
For the proliferation assay, asynchronously growing MEFs were pulse la-
beled with 3 mg/ml BrdU for 4 hr and then fixed with 70% ethanol. Cells
were permeabilized, and DNA was denatured for 1 hr with 2 M HCl containing
0.5% Triton X-100, followed by neutralization with 0.1 M sodium borate and
rinsing with PBS. Cells were then incubated overnight with mouse anti-BrdU
(Dako; diluted 1:200). Cells were rinsed with PBS and then incubated for 2 hr
with FITC-conjugated anti-mouse IgG (Vector; 1:200) and were counter-
stained with DAPI prior to counting.
Cotransformation focus formation assays
Primary MEFs (13 105) were plated in a 6 cm dish for infection with pL56-Ras
or LMIRMyc-Ras retrovirus. Following infection, cells were allowed to grow
7–10 days past confluency. Plates were rinsed with PBS, fixed with metha-
nol, dried, and then stained with a 2% methylene blue solution (in 50% meth-
anol in H2O). The total number of foci per plate was scored. Experiments
were performed in triplicate with cells derived from three different groups
of littermates.
Soft agarose assays
Cells (2.53 105) were resuspended in 10% FBS in DMEM containing 0.35%
agarose and plated onto a layer of 0.7% agarose-containing medium in
a 6-well dish. Once the medium was solidified, 10% FBS in DMEM was
added and was changed weekly. For Ras transformation, polyclonal cell lines
were generated by infecting immortalized MEFs with pBabe-hygro or pBabe-
hygro-H-Rasvaline12 retrovirus and were selected with 150 mg/ml hygromycin
until all uninfected cells were dead. For coexpression of Bcl-2, cells were
reinfected with high-titer pBabeGFP-Bcl-2 or pBbabeGFP retroviruses. Col-
onies were quantitated by counting every colony on a plate or colonies from
ten random fields. Experiments were performed three times, in triplicate,
using independently derived cell lines.
Protein analysis
Protein cell lysates were prepared as previously described (Hahn-Windgas-
sen et al., 2005). SDS-PAGE gels (6%, 8%, 10%, or 12%) were used depend-
ing on the protein of interest. Anti-cyclin D1, anti-cyclin D2, anti-cyclin D3,
and anti-cyclin B were from Neomarkers. Anti-total pRb was from BD Phar-
mingen or Neomarkers. Phosphorylation-specific antibodies for pan-Akt,
pSer473 Akt, S6K1, pT389S6K1, pSer780pRb, and pSer807/811pRb were
from Cell Signaling Technology. Anti-p27 was from BD Biosciences. Anti-
CDK4, anti-cyclin E, and anti-tuberin (TSC2) were purchased from Santa
Cruz Biotechnology. Anti-p53 was from Calbiochem (Oncogene Research),
and anti-b-actin was from Sigma. Anti-Raptor and anti-4EBP1 were kindly
provided by Nahum Sonenberg (McGill University). HRP-conjugated anti-
bodies (rabbit anti-mouse, goat anti-rabbit, and rabbit anti-sheep) were
from Zymed.
Skin carcinogenesis protocol
Seven-week-old littermates, WT or Akt1 KO C57BL/6:129sv (1:1) mice, were
shaved on the dorsal surface and allowed to recover for 48 hr. A one-time
dose of 25 mg DMBA (Sigma) in 200 ml of ethanol was applied to the shavedCANCER CELL OCTOBER 2006
A R T I C L Esurface. After 1 week, 3.7 mg of TPA (LC Laboratories) in 200 ml of ethanol was
applied twice weekly for the duration of the experiment. Each week, calipers
were used to determine the size of each tumor. Nine mice per genotype were
subjected to this protocol. Mice of each genotype that received vehicle alone
did not develop tumors.
Monitoring mammary and salivary gland tumors in MMTV-v-H-Ras
transgenic mice
MMTV-v-H-Ras mice (Sinn et al., 1987) were purchased from Charles River.
Akt1+/2/MMTV-v-H-Ras mice were intercrossed to generate Akt1+/+/MMTV-
v-H-Ras and Akt12/2/MMTV-v-H-Ras mice. Mice were monitored weekly for
tumor appearance.
Supplemental data
The Supplemental Data include Supplemental Experimental Procedures and
four supplemental figures and can be found with this article online at http://
www.cancercell.org/cgi/content/full/10/4/269/DC1/.
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